CN109999026A - 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 - Google Patents
一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 Download PDFInfo
- Publication number
- CN109999026A CN109999026A CN201910320027.1A CN201910320027A CN109999026A CN 109999026 A CN109999026 A CN 109999026A CN 201910320027 A CN201910320027 A CN 201910320027A CN 109999026 A CN109999026 A CN 109999026A
- Authority
- CN
- China
- Prior art keywords
- thiophene
- foot
- compound
- carboxamide
- mouth disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 32
- -1 Thiophene methanamide compound Chemical class 0.000 title claims abstract description 21
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 claims description 12
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- ZBCLRHLHVBZLHS-UHFFFAOYSA-N BrC1=CC=C(CN(C(=O)C=2SC=CC=2)C2=CC=CC=C2)C=C1 Chemical compound BrC1=CC=C(CN(C(=O)C=2SC=CC=2)C2=CC=CC=C2)C=C1 ZBCLRHLHVBZLHS-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- MUBWXQOSNBXCSJ-UHFFFAOYSA-N n-benzyl-n-phenylthiophene-2-carboxamide Chemical compound C=1C=CSC=1C(=O)N(C=1C=CC=CC=1)CC1=CC=CC=C1 MUBWXQOSNBXCSJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 2
- 101000713305 Homo sapiens Sodium-coupled neutral amino acid transporter 1 Proteins 0.000 description 2
- 101000640813 Homo sapiens Sodium-coupled neutral amino acid transporter 2 Proteins 0.000 description 2
- 101000716973 Homo sapiens Thialysine N-epsilon-acetyltransferase Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241001493546 Suina Species 0.000 description 2
- 102100020926 Thialysine N-epsilon-acetyltransferase Human genes 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical group NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用,属于医药技术领域。该噻吩甲酰胺类化合物或其药理或生理上可接受的盐,可以有效抑制口蹄疫病毒的复制,且对细胞的毒性较低,显示此类化合物在制备抗口蹄疫药物中的应用前景。
Description
技术领域
本发明属于医药技术领域,涉及一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用。
背景技术
口蹄疫(foot-and-mouth disease,FMD)是由口蹄疫病毒引起的烈性传染病,主要感染偶蹄动物,患病动物的口、舌、唇、蹄、乳房等部位发生水泡并破溃形成烂斑。人和非偶蹄动物也可被感染,但症状较轻。猪、牛、羊等主要的家畜均可感染此病,并形成全球大规模流行,所以国际兽疫局(OIE)将该病列为A类家畜传染病之首。该病的发病率几乎达100%,一般病程呈良性经过,死亡率只有2%~3%,犊牛及仔猪和被恶性病型感染,死亡率可达50%~70%。除动物死亡造成直接经济损失外,动物在患病期间肉和奶的生产停止、病后肉和奶产量长期减少以及种用价值丧失也可造成较大的损失。最为严重的是该病传染性极强,对病畜和怀疑处于潜伏期间的同群动物必须紧急处理,对疫点周围的广大范围必须隔离封锁,禁止动物移动和畜产品调运上市。由此导致该地区甚至该国家的畜产品进出口贸易停止,造成巨大的经济损失和政治影响。
口蹄疫病原是口蹄疫病毒(foot-and-mouth disease virus,FMDV)。FMDV是小RNA病毒科(Picornaviridae),口蹄疫病毒属(Aphthovirus)的成员。到目前为止,已发现了7个血清型,即O、A、C型(称欧洲型),SAT1、SAT2、SAT3(南非1、2、3型,称非洲型)和AsiaⅠ(亚洲Ⅰ型,称亚洲型),7个血清型可根据核酸同源性大小分为两群,O、A、C和AsiaⅠ为第1群,SAT1、SAT2、SAT3为第2群。群内各型同源性达60%~70%,但两群之间同源性仅为25%~40%,血清型间无血清交叉和交叉免疫现象。即使在同一血清型内不同病毒的抗原性亦有变化。
当前采用疫苗来防控口蹄疫存在很大的缺陷,因此有必要研究新的抗病毒策略以应对该疾病的威胁。一些科研工作者尝试采用干扰素和RNA干扰技术来防控口蹄疫,虽然在细胞水平取得一些进展,但却都未能投入使用。
目前较少有采用化学小分子来防控口蹄疫的报道,设计合成一系列能够较好抑制口蹄疫病毒(FMDV)的活性化合物对于研制口蹄疫药物是十分有利的。申请人于2015年发现并合成了一类基于噻吩甲酰胺骨架的化合物(Jiawei Pan et al,Synthesis of N-benzyl-N-phenylthiophere-2-carboxamide analogues as a novel class ofenterovirus 71ihibitors,RSC Adv,2015,5,55100-55108),该类化合物具有抑制肠道病毒EV71的作用。由于口蹄疫病毒和EV71的致病机制无直接相关性,这类化合物是否可作为口蹄疫病毒抑制剂,还不得而知。
发明内容
为了克服现有技术存在的缺陷与不足,本发明的首要目的是提供一种噻吩甲酰胺类化合物在制备抗口蹄疫病毒药物中的应用。该类化合物对细胞的毒性小,在口蹄疫的预防和治疗方面有一定的应用前景。
为了实现上述目的,本发明采用如下技术方案:
第一方面,本发明提供一种噻吩甲酰胺类化合物或其药理或生理上可接受的盐在制备抗口蹄疫病毒药物中的应用,所述噻吩甲酰胺类化合物的结构如以下通式(I)所示:
其中,
R1为
R2为H、2-F、3-F、4-F、4-Cl、4-Br、4-Me、4-OMe、4-OH、3-Me或3-CF3;
R3为H、4-F、4-Cl、4-Br、4-NO2、4-CN、4-OMe、4-OH、3-Br、2-Br或2-Br-4-F。
优选地,上述应用中,所述噻吩甲酰胺类化合物的结构如下表1所示的化合物:
表1
进一步地,上述应用中,所述噻吩甲酰胺类化合物是下列化合物:
N-(4-溴苄基)-N-(4-氟苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-氟苯基)呋喃-2-甲酰胺、
N-苄基-N-苯基噻吩-2-甲酰胺、
N-(4-溴苄基)-N-苯基噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(4-氟苯基)噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(对甲苯基)噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(4-氯苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-溴苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(间甲苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-氯苯基)噻吩-2-甲酰胺、
N-(4-氟苯基)-N-(4-甲氧基苄基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(2-氟苯基)噻吩-2-甲酰胺。
第二方面,本发明提供一种药物组合物在制备抗口蹄疫病毒药物中的应用,所述药物组合物包含上述噻吩甲酰胺类化合物或其药理或生理上可接受的盐,以及药学上可接受的载体或赋形剂。
本发明涉及的噻吩甲酰胺类化合物,可以有效抑制口蹄疫病毒的复制,其对细胞的毒性小,可用于制备抗口蹄疫药物。
具体实施方式
通过以下详细说明可以进一步理解本发明的特点和优点。所提供的实施例仅是对本发明方法的说明,而不以任何方式限制本发明揭示的其余内容。
实验例1:噻吩甲酰胺类化合物生物活性测试
(1)噻吩甲酰胺类化合物细胞毒性测定:
黄色的噻唑兰,简称MTT,可透过细胞膜进入细胞内,活细胞线粒体中的琥珀脱氢酶能使外源性MTT还原为难溶于水的蓝紫色的针状Formazan结晶并沉积在细胞中,结晶物可被20%(质量比体积)SDS溶解,用酶联免疫检测仪在595nm波长处测定其光吸收值,可间接反映细胞数量。
实验时,将BHK-21细胞以每孔2×104的密度传至96孔板中,在37℃培养24小时后,吸走培养基,将含有各种浓度梯度化合物的细胞培养基加到每个孔。24小时后,每孔加入5mg/mL的MTT溶液,细胞板在37℃的CO2孵化器中培养4h。接着将助溶液加入到溶血细胞,在37℃孵化3h,酶标仪测定595nm波长下的OD值。化合物的抑制率(%)=[1-(E-N)/(P-N)]×100,其中“E”代表给药组的OD值,“P”代表未给药组的OD值,“N”代表空白组OD值。化合物的半数抑制浓度(CC50)作为该化合物细胞毒性的指标。
(2)噻吩甲酰胺类化合物抗口蹄疫病毒活性实验:
通过病毒蚀斑数减少分析来评估化合物的抗病毒活性。铺满BHK-21细胞的6孔板按照70PFU/孔接入口蹄疫病毒(FMDV,Akesu/58/2002),40分钟后除去含病毒培养基并加入含有特定浓度待测药物的培养基,培养基含有终浓度为0.5%agarose。在37℃5%CO2条件下培养48-72小时后,用3%的福尔马林固定细胞,用0.5%结晶紫对细胞进行染色并计算病毒蚀斑数。EC50是指特定药物有效抑制病毒产生蚀斑数至对照孔的50%所需的浓度。
表2本发明合成的目标化合物PJW 1-33抗EV71活性
上述实验结果表明:合成的化合物大多数具有很好的抗口蹄疫病毒活性,例如化合物PJW 1(EC50=0.083μM,SI=283.5)、PJW 2(EC50=0.076μM,SI=886.3)、PJW 6(EC50=0.094μM,SI=804.5)、PJW 7(EC50=0.120μM,SI=306.5)、PJW 10(EC50=0.211μM,SI=248.2)等,尤其是化合物PJW 2、PJW 6和PJW 7显示出非常好的抗口蹄疫病毒活性和非常高的选择性。显示该类化合物在口蹄疫的预防和治疗方面有很强的应用前景。
Claims (4)
1.一种噻吩甲酰胺类化合物或其药理或生理上可接受的盐在制备抗口蹄疫病毒药物中的应用,其特征在于,所述噻吩甲酰胺类化合物的结构如以下通式(I)所示:
其中,
R1为
R2为H、2-F、3-F、4-F、4-Cl、4-Br、4-Me、4-OMe、4-OH、3-Me或3-CF3;
R3为H、4-F、4-Cl、4-Br、4-NO2、4-CN、4-OMe、4-OH、3-Br、2-Br或2-Br-4-F。
2.根据权利要求1所述的噻吩甲酰胺类化合物或其药理或生理上可接受的盐在制备抗口蹄疫病毒药物中的应用,其特征在于,所述噻吩甲酰胺类化合物的结构如下表所示的化合物:
3.根据权利要求1或2所述的应用,其特征在于,所述噻吩甲酰胺类化合物是下列化合物:
N-(4-溴苄基)-N-(4-氟苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-氟苯基)呋喃-2-甲酰胺、
N-苄基-N-苯基噻吩-2-甲酰胺、
N-(4-溴苄基)-N-苯基噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(4-氟苯基)噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(对甲苯基)噻吩-2-甲酰胺、
N-(4-氯苄基)-N-(4-氯苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-溴苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(间甲苯基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(4-氯苯基)噻吩-2-甲酰胺、
N-(4-氟苯基)-N-(4-甲氧基苄基)噻吩-2-甲酰胺、
N-(4-溴苄基)-N-(2-氟苯基)噻吩-2-甲酰胺。
4.一种药物组合物在制备抗口蹄疫病毒药物中的应用,其特征在于所述药物组合物包含权利要求1-3任一项所述的噻吩甲酰胺类化合物或其药理或生理上可接受的盐,以及药学上可接受的载体或赋形剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910320027.1A CN109999026B (zh) | 2019-04-19 | 2019-04-19 | 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910320027.1A CN109999026B (zh) | 2019-04-19 | 2019-04-19 | 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109999026A true CN109999026A (zh) | 2019-07-12 |
CN109999026B CN109999026B (zh) | 2021-08-03 |
Family
ID=67173248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910320027.1A Expired - Fee Related CN109999026B (zh) | 2019-04-19 | 2019-04-19 | 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109999026B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116156A2 (en) * | 2007-03-21 | 2008-09-25 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
-
2019
- 2019-04-19 CN CN201910320027.1A patent/CN109999026B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116156A2 (en) * | 2007-03-21 | 2008-09-25 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
Non-Patent Citations (1)
Title |
---|
JIAWEI PAN ET AL.: "Synthesis of N-benzyl-N-phenylthiophene-2-carboxamide analogues as a novel class of enterovirus 71 inhibitors", 《RSC ADV》 * |
Also Published As
Publication number | Publication date |
---|---|
CN109999026B (zh) | 2021-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113289018A (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
Eggers | Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. | |
CN113679726A (zh) | 丹参提取物和醌类化合物在抗冠状病毒中的应用 | |
CN112546038A (zh) | 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用 | |
CN113827596B (zh) | 拉帕替尼和/或其可药用衍生物在制备抗肠道病毒药物中的应用 | |
CN106880630B (zh) | Retro-2cycl及相关衍生物的用途 | |
CN109999026B (zh) | 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用 | |
CN115844879B (zh) | 褪黑素在抗盖塔病毒中的应用 | |
CN102335171B (zh) | 一类n-(2-噻唑)苯甲酰胺衍生物的应用 | |
US20210361619A1 (en) | Composition for preventing or treating sars coronavirus 2 infection disease | |
CN113440527B (zh) | 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用 | |
CN104203265A (zh) | 抗黄病毒的抗病毒组合物 | |
US10064843B2 (en) | Bis-amide derivative and use thereof | |
CN110974816A (zh) | 双官能团碘代羧酸作为柯萨奇病毒抑制剂的应用 | |
CN114748481B (zh) | 特罗司他马尿酸盐在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用 | |
EP3960173B1 (en) | Enterovirus inhibitor | |
KR101832056B1 (ko) | 항 콕사키바이러스 활성을 갖는 백두구 추출물 | |
CN103070876B (zh) | 一类抗乙型脑炎病毒感染的组合物及其应用 | |
CN115778946B (zh) | 化合物zpp在制备抗病毒药物中的应用 | |
CN117159539B (zh) | 褪黑素在抗猪轮状病毒中的应用 | |
CN113827586B (zh) | 盐酸去甲替林在制备抗肠道病毒药物中的应用 | |
TW201629035A (zh) | 抗病毒化合物、醫藥組合物及其使用方法 | |
CN113768920A (zh) | 槲皮素和/或其可药用衍生物在制备抗肠道病毒药物中的应用 | |
CN116585317A (zh) | 石蒜碱β-芳基丙烯酸酯衍生物在制备抗病毒药物中的应用 | |
JP2023525855A (ja) | コロナウイルスによる疾患の治療及び/又は予防のための化合物及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210803 |